StemCell Therapy

A study has revealed that in rhesus monkeys, a genetic mutation could be the cause of Bardet-Biedl Syndrome, providing a way to study the disease and develop therapies.

Researchers have discovered a genetic mutation in rhesus monkeys that leads to the rare Bardet-Biedl Syndrome (BBS). According to the team, their findings offer a promising way to develop gene and cell therapies to treat the condition in human patients.

The research was conducted at the Oregon Health & Science University (OHSU), US and offers the first known naturally occurring nonhuman primate model of the syndrome which causes vision loss, kidney dysfunction and extra fingers or toes.

their discovery could also be used to develop treatments for other retinitis pigmentosa diseases

Two related monkeys without cells critical for vision were discovered by the researchers. Examining their genomes, they found that both monkeys had a mutation in the BBS7 gene, one of at least 14 genes associated with BBS.

The team then searched a genome database of the monkeys at the Oregon National Primate Research Center at OHSU. They identified a third monkey that had the same mutation and has severe BBS symptoms.

The group are now breeding more animals with the naturally occurring BBS7 mutation, as having more animals with the mutation can enable them to develop cell and gene therapies.

There is no cure for BBS today but having a naturally occurring animal model for the condition could help us find one in the future, said the papers corresponding author, Dr Martha Neuringer, a professor of neuroscience at the Oregon National Primate Research Center at OHSU.

The researchers say that their discovery could also be used to develop treatments for other retinitis pigmentosa diseases.

The results were published in Experimental Eye Research.

Go here to read the rest:
Genetic mutation in monkeys identified as cause of Bardet-Biedl Syndrome - Drug Target Review

This entry was posted on October 28, 2019 at 1:47 pm and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |